Novartis, Glenmark, Centrient Act To Tackle COVID-19 Crisis
As Beximco Generates Employment With PPE Manufacturing
Executive Summary
While Novartis is continuing to provide hydroxychloroquine for ongoing investigator-initiated trials and support for study of a potential vaccine, it has decided to stop sponsoring hydroxychloroquine clinical trials. Meanwhile, Natco has announced donations of chloroquine phosphate for clinical trials, while Centrient and Beximco have provided PPE for healthcare workers.